{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T17:38:42Z","timestamp":1715967522663},"reference-count":28,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":2808,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS spectr."],"published-print":{"date-parts":[[2007,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Introduction:<\/jats:bold> Because major depressive disorder (MDD) is often chronic and recurrent, even pediatric patients who are treated successfully during an acute episode may need longer-term treatment. Yet, data on long-term treatment with antidepressants in pediatric MDD are limited.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> To evaluate long-term effectiveness and safety of treatment with venlafaxine extended-release (ER) in children and adolescents with MDD.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Subjects (n=86) 7\u201317 years of age with MDD entered a multicenter, open-label study of flexible-dose venlafaxine ER for 6 weeks of acute treatment, followed by continuation treatment for up to 6 months total treatment. The primary efficacy variable was the Children's Depression Rating Scale-Revised (CDRS-R) total score (intent-to-treat population).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Mean CDRS-R total score decreased from 60.1\u00b110.0 at baseline to 36.3\u00b113.1 at week 6, and to 33.8\u00b115.0 at 6 months (last observation carried forward). Among completers (n=36), the mean CDRS-R total score was 24.3\u00b17.6 at the end of 6 months of treatment. The most frequent treatment-emergent adverse events were headache (53%), nausea (26%), infection (24%), abdominal pain (22%), vomiting (21%), and pharyngitis (19%). Fifteen (17%) participants discontinued due to adverse events, 9 of whom did so within the first 6 weeks. Serious adverse events (suicide attempt [two], hostility [two], hallucinations, depression, and pharyngitis) occurred in seven patients. There were no suicides.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Most improvement with venlafaxine ER occurs during the first 6 weeks of treatment. Prescribers should be alert to signs of suicidal ideation and hostility in pediatric patients.<\/jats:p>","DOI":"10.1017\/s1092852900020940","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:53:28Z","timestamp":1470099208000},"page":"223-233","source":"Crossref","is-referenced-by-count":11,"title":["Long-Term, Open-Label Venlafaxine Extended-Release Treatment in Children and Adolescents with Major Depressive Disorder"],"prefix":"10.1017","volume":"12","author":[{"given":"Graham J.","family":"Emslie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul P.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia R.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900020940_ref028","doi-asserted-by":"publisher","DOI":"10.1097\/01.CHI.0000046841.56865.37"},{"key":"S1092852900020940_ref023","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"S1092852900020940_ref022","first-page":"217","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S1092852900020940_ref021","first-page":"979","article-title":"Children's depression rating scale-revised","volume":"21","author":"Poznanski","year":"1985","journal-title":"Psychopharmacol Bull"},{"key":"S1092852900020940_ref020","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199707000-00021"},{"key":"S1092852900020940_ref019","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199911000-00020"},{"key":"S1092852900020940_ref016","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2003.10.004"},{"key":"S1092852900020940_ref015","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0307"},{"key":"S1092852900020940_ref011","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.103"},{"key":"S1092852900020940_ref010","doi-asserted-by":"publisher","DOI":"10.1089\/104454601750284036"},{"key":"S1092852900020940_ref007","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.6.1079"},{"key":"S1092852900020940_ref006","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.8.1033"},{"key":"S1092852900020940_ref018","volume-title":"J Am Acad Child Adolesc Psychiatry","author":"Emslie"},{"key":"S1092852900020940_ref005","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830230069010"},{"key":"S1092852900020940_ref004","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199611000-00011"},{"key":"S1092852900020940_ref003","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200106000-00012"},{"key":"S1092852900020940_ref002","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-7358(98)00010-5"},{"key":"S1092852900020940_ref026","unstructured":"Hammad TA . and the Center for Drug Evaluation and Research, FDA: Review and Evaluation of Clinical Data, 2004;1\u2013131. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/briefing\/2004-4065b1-10-TABO8-Hammads-Review.pdf. Accessed November 14, 2006."},{"key":"S1092852900020940_ref008","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000192250.38400.9e"},{"key":"S1092852900020940_ref025","volume-title":"Dear Healthcare Professional (venlafaxine)","author":"Kusiak","year":"2003"},{"key":"S1092852900020940_ref001","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199811000-00029"},{"key":"S1092852900020940_ref014","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.3.332"},{"key":"S1092852900020940_ref017","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n0904"},{"key":"S1092852900020940_ref024","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000242228.75516.21"},{"key":"S1092852900020940_ref013","unstructured":"FDA Public Health Advisory: Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. Issued October 15, 2004. Available at: http:\/\/www.fda.gov\/cder\/drug\/antidepressants\/SSRIPHA200410.htm. Accessed November 14, 2006."},{"key":"S1092852900020940_ref027","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.131"},{"key":"S1092852900020940_ref012","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000140453.89323.57"},{"key":"S1092852900020940_ref009","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7610.2005.01467.x"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900020940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T20:10:26Z","timestamp":1556741426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900020940\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S1092852900020940"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900020940","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}